How well does a new immune treatment work for advanced lung cancer

This is an observational study—meaning researchers will follow patients who are already receiving or eligible for adebrelimab, a new immune therapy medication for advanced small cell lung cancer. The study will track how well the medication works and what side effects patients experience, all in real clinical settings rather than in a controlled research environment.

While this medication has shown promise, researchers want to understand how it performs in everyday practice with diverse patients and real-world conditions—including those with brain or liver spread of cancer. This information helps doctors understand which patients benefit most and what safety concerns to watch for.